|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-7-11
|
|
pubmed:abstractText |
Endocrine therapies for breast cancer that target the estrogen receptor (ER) are ineffective in the 25%-30% of cases that are ER negative (ER-). Androgen receptor (AR) is expressed in 60%-70% of breast tumors, independent of ER status. How androgens and AR regulate breast cancer growth remains largely unknown. We find that AR is enriched in ER- breast tumors that overexpress HER2. Through analysis of the AR cistrome and androgen-regulated gene expression in ER-/HER2+ breast cancers we find that AR mediates ligand-dependent activation of Wnt and HER2 signaling pathways through direct transcriptional induction of WNT7B and HER3. Specific targeting of AR, Wnt or HER2 signaling impairs androgen-stimulated tumor cell growth suggesting potential therapeutic approaches for ER-/HER2+ breast cancers.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Androgens,
http://linkedlifedata.com/resource/pubmed/chemical/Anilides,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydrotestosterone,
http://linkedlifedata.com/resource/pubmed/chemical/FOXA1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/HER2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatocyte Nuclear Factor 3-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Androgen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Tosyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Wnt Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/beta Catenin,
http://linkedlifedata.com/resource/pubmed/chemical/bicalutamide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1878-3686
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
12
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
119-31
|
|
pubmed:dateRevised |
2011-9-30
|
|
pubmed:meshHeading |
pubmed-meshheading:21741601-Androgens,
pubmed-meshheading:21741601-Anilides,
pubmed-meshheading:21741601-Animals,
pubmed-meshheading:21741601-Breast Neoplasms,
pubmed-meshheading:21741601-Cell Line, Tumor,
pubmed-meshheading:21741601-Cell Proliferation,
pubmed-meshheading:21741601-Dihydrotestosterone,
pubmed-meshheading:21741601-Female,
pubmed-meshheading:21741601-Gene Expression Profiling,
pubmed-meshheading:21741601-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:21741601-Hepatocyte Nuclear Factor 3-alpha,
pubmed-meshheading:21741601-Humans,
pubmed-meshheading:21741601-Mice,
pubmed-meshheading:21741601-Nitriles,
pubmed-meshheading:21741601-Receptor, erbB-2,
pubmed-meshheading:21741601-Receptors, Androgen,
pubmed-meshheading:21741601-Receptors, Estrogen,
pubmed-meshheading:21741601-Signal Transduction,
pubmed-meshheading:21741601-Tosyl Compounds,
pubmed-meshheading:21741601-Transcriptional Activation,
pubmed-meshheading:21741601-Up-Regulation,
pubmed-meshheading:21741601-Wnt Proteins,
pubmed-meshheading:21741601-Xenograft Model Antitumor Assays,
pubmed-meshheading:21741601-beta Catenin
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Targeting androgen receptor in estrogen receptor-negative breast cancer.
|
|
pubmed:affiliation |
Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, N.I.H., Extramural
|
